News - Neurological, Markets & Marketing

Filter

Popular Filters

1 to 25 of 164 results

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole

26-06-2014

Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant…

brexpiprazoleBrintellixLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Top 5% of opioid prescribers write 40% of US narcotic prescriptions

Top 5% of opioid prescribers write 40% of US narcotic prescriptions

09-06-2014

In the USA, 40% of narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers,…

Markets & MarketingNeurologicalPharmaceuticalUSA

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Major depressive disorder treatment market to grow to $9.7 billion by end 2023, after downturn until 2017

23-05-2014

New research forecasts that the therapeutics market for major depressive disorder (MDD) will face a dynamic…

Business FinanceGlobalGlobalDataLundbeckMarkets & MarketingNeurologicalPharmaceuticalTedatioxetineValby

Eisai’s Fycompa debuts in France following reimbursement agreement

21-05-2014

Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

14-05-2014

US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Consumption of opioid drugs in Southern Europe up by 15%, World Medicine Park congress hears

12-05-2014

The congress of the World Medicine Park, the first global forum devoted to medical sciences, this year…

EuropeMarkets & MarketingNeurologicalPharmaceutical

Teva and Dr Reddy’s latest to launch generic Lunesta in USA

16-04-2014

Two more companies have debuted generic versions of the insomnia drug Lunesta (eszopiclone) tablets,…

Dainippon Sumitomo PharmaDr Reddy's LaboratoriesGenericsLunestaMarkets & MarketingNeurologicalNorth AmericaSunovion PharmaceuticalsTeva Pharmaceutical IndustriesUSA

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

11-04-2014

The US Food and Drug Administration’s recent approval of Johnson & Johnson subsidiary Janssen’s Topamax…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalPharmaceuticalRegulationTopamax

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023

13-03-2014

The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Japan’s market for schizophrenia treatment to double by 2022

Japan’s market for schizophrenia treatment to double by 2022

12-03-2014

Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade,…

Asia-PacificJapanMarkets & MarketingNeurologicalPharmaceutical

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Endo agrees $193 million settlement with US Justice Dept over Lidoderm

23-02-2014

US drugmaker Endo Health Solutions and its subsidiary Endo Pharmaceuticals have agreed to pay $192.7…

Endo Health SolutionsFinancialLegalLidodermMarkets & MarketingNeurologicalPharmaceutical

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing

11-02-2014

The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Lundbeck’s Brintellix available in US pharmacies for depression

Lundbeck’s Brintellix available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

1 to 25 of 164 results

Back to top